Theracryf (TCF)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

 NULL
   
  • Closing Price Chg:
      0.000p
  • 52 Week High: NUL
  • 52 Week Low: 0.000p
  • Currency: UK Pounds
  • Shares Issued: 2,148.96m
  • Volume: 0

Latest ShareCast News

TheraCryf signs deal for Ox-1 addiction treatment development

By Josh White

Date: Monday 12 May 2025

(Sharecast News) - TheraCryf announced on Monday that it has entered into a master service agreement with contract research organisation Pharmaron UK to support the development of its Orexin-1 addiction treatment programme.

Evgen upbeat on start of glioblastoma research project

By Josh White

Date: Thursday 26 Oct 2023

(Sharecast News) - Clinical-stage drug developer Evgen Pharma announced on Thursday that it has partnered with Dr Marjolein Geurts, a neuro-oncologist at Erasmus University Medical Centre, to start a ground-breaking research initiative in glioblastoma.

Evgen Pharma doses first volunteers in SFX-01 trial

By Josh White

Date: Wednesday 16 Nov 2022

(Sharecast News) - Clinical-stage drug developer Evgen Pharma has dosed the first group of healthy volunteers in its placebo-controlled, dose-escalating, randomised phase 1 and 1b clinical trial, it announced on Wednesday.

Evgen starts recruiting volunteers for trial of ... 12-Oct-2022 ShareCast
Evgen agrees fresh licensing deal with Spanish i... 18-Jan-2022 ShareCast
Evgen pleased with preclinical data on SFX-01 13-Jul-2021 ShareCast
Evgen 'surprised and disappointed' by findings i... 09-Jul-2021 ShareCast
Evgen upbeat on new data on potential breast can... 14-Jun-2021 ShareCast
Evgen appoints Helen Kuhlman as chief business o... 22-Mar-2021 ShareCast
Evgen Covid-19 trial given all-clear on safety a... 11-Mar-2021 ShareCast
Evgen makes progress with recruitment in 'STAR' ... 17-Feb-2021 ShareCast
Evgen announces positive preclinical data for SF... 22-Jan-2021 ShareCast
Evgen reports 'highly positive' data from SFX-01... 21-Jan-2021 ShareCast
Evgen Pharma makes progress with 'STAR' trial re... 19-Jan-2021 ShareCast
Evgen Pharma performs in line with forecasts in ... 10-Dec-2020 ShareCast
Evgen doses first patients in 'STAR' respiratory... 23-Nov-2020 ShareCast
Evgen gets full approval for SFX-01 trial in Cov... 23-Oct-2020 ShareCast
Evgen Pharma licences technology to Juvenescence 15-Sep-2020 ShareCast
Evgen's 'SFX-01' to be tested with Covid-19 pati... 17-Jun-2020 ShareCast
Losses widen as Evgen Pharma develops SFX-01 15-Jun-2020 ShareCast
 

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

Theracryf Market Data

Currency UK Pounds
Share Price NULL
Closing Price Change 0.000p
% Change 0.00 %
52 Week High NUL
52 Week Low 0.000p
Volume 0
Shares Issued 2,148.96m

Theracryf Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
5.95% above the market average5.95% above the market average5.95% above the market average5.95% above the market average5.95% above the market average
85.37% above the sector average85.37% above the sector average85.37% above the sector average85.37% above the sector average85.37% above the sector average
Price Trend
97.44% below the market average97.44% below the market average97.44% below the market average97.44% below the market average97.44% below the market average
95.56% below the sector average95.56% below the sector average95.56% below the sector average95.56% below the sector average95.56% below the sector average
Income Not Available
Growth Not Available

Theracryf Dividends

No dividends found

Trades for --2025

Time Volume / Share Price
0 @ 0.000p

Theracryf Key Personnel

CEO Huw Jones
CFO Toni Hänninen

Top of Page